Welcome to our dedicated page for Nanoviricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on Nanoviricides stock.
NanoViricides, Inc. develops clinical-stage antiviral therapeutics based on its nanoviricide technology and host-mimetic nanomedicine approach. Company news centers on NV-387, its lead broad-spectrum antiviral candidate, including clinical development for MPox, respiratory viral infections, measles and other viral diseases, as well as manufacturing updates for clinical product forms such as NV-387 Oral Gummies.
Recurring updates also cover FDA orphan-drug designation activity, rare-disease regulatory strategy, investor-conference participation and the company’s relationship with TheraCour Pharma for antiviral drug development technology. The news flow is focused on antiviral pipeline progress, regulatory designations and disease-area positioning rather than commercial product sales.
NanoViricides (NYSE American: NNVC) reported National Ethics Committee approval in the Democratic Republic of Congo for a planned Phase II clinical trial of its oral antiviral candidate NV-387 gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company is preparing a clinical trial application to the DRC regulator ACOREP, leveraging documents previously used for an approved Phase II Mpox trial of the same drug in DRC. NV-387 oral gummies have already been shipped to DRC for the Mpox program, providing on-site drug supply for the proposed Ebola study. According to NanoViricides, NV-387 is a broad-spectrum, orally administered antiviral designed to target host-cell features used by many viruses, and is believed by the company to have potential activity against multiple ebolaviruses and other filoviruses.
NanoViricides (NYSE American: NNVC) announced that Noble Capital Markets initiated independent research coverage on July 6, 2026, with an “Outperform” rating and a $6.00 target price. The report reviews current and longer-term antiviral programs.
Separately, a June 29, 2026 fireside chat with President Dr. Anil Diwan on the company’s broad-spectrum antiviral technology, Orphan Drug Designation for measles-related work, and the lead candidate NV-387—now being advanced toward Phase II trials—was published by StockInvestor Daily and is available on the company’s website.
NanoViricides (NYSE American: NNVC) reports progress toward a Phase II clinical trial of NV-387 Oral Gummies for treating Bundibugyo ebolavirus in DR Congo. A trial proposal has been approved by the DRC Pillar Committee, and NV-387 is already cleared by ACOREP for a Phase II Mpox trial with drug product shipped to DRC.
NV-387 is described as a broad-spectrum, orally delivered antiviral that mimics host-cell HSPG, aiming to offer an alternative to infusion-based Ebola treatments, pending ethics and regulatory approvals and demonstration of clinical effectiveness.
NanoViricides (NYSE American: NNVC) reported that its clinical-stage antiviral NV-387 received US FDA Rare Pediatric Disease Drug designation as a treatment for measles, adding to its existing Orphan Drug status. This makes NV-387 eligible for a future Priority Review Voucher (PRV), which can be used or sold after a successful marketing application, potentially providing significant non-dilutive funding. NV-387 has shown strong activity against lethal measles infection in a humanized animal model and is part of a broad-spectrum antiviral pipeline that the company aims to advance into Phase II trials.
NanoViricides (NYSE:NNVC) has shipped its NV-387 oral gummies drug product to the Democratic Republic of Congo for a Phase II clinical trial treating MPox (monkeypox), enabling patient enrollment. According to NanoViricides, regulators in DRC have approved the trial, and an Ebola-focused Phase II trial proposal has been accepted.
The company has applied for US FDA Orphan Drug Designation for NV-387 in MPox, which it estimates could yield benefits worth tens of millions of dollars and position NV-387 for future pandemic-response contracts if clinical results are successful.
NanoViricides (NYSE American: NNVC) announced that its proposal for a Phase II clinical trial of NV-387 oral gummies to treat Bundibugyo ebolavirus in DR Congo has been approved by the DRC Pillar Committee. NV-387 is a broad-spectrum, orally administered antiviral already cleared in DRC for a Phase II Mpox trial. Next steps include submissions to the DRC National Ethics Committee and regulatory agency ACOREP before the Ebola trial can begin.
NanoViricides (NYSE American: NNVC) has proposed a Phase II clinical trial of its NV-387 oral gummies to treat the current Bundibugyo ebolavirus outbreak in the DRC. NV-387 is a broad-spectrum antiviral given orally, designed to target host-cell attachment mechanisms and reduce viral escape across multiple filoviruses.
NanoViricides (NYSE American:NNVC) reports that its broad-spectrum antiviral candidate NV-387 may be a treatment option for the current Ebola Bundibugyo outbreak, which has over 900 suspected cases and 220+ deaths and no approved therapies.
NV-387 showed longer survival than remdesivir in a lethal COVID-19 animal model and targets heparan sulfate proteoglycans used by many viruses. Oral NV-387 gummies are stable at room temperature and are ready to be shipped to DRC for an impending Phase II Mpox trial, potentially enabling rapid evaluation in Ebola patients.
NanoViricides (NYSE American: NNVC) closed a registered direct offering to a single institutional investor, raising aggregate gross proceeds of approximately $2,000,001.
The securities were priced at-the-market at $1.50 per share with accompanying warrants exercisable at $1.75 per share after six months, expiring in three years.
NanoViricides (NYSE American: NNVC) highlights NV-387, a broad-spectrum antiviral, as a potential oral treatment for the Bundibugyo Ebola outbreak in eastern DRC and Uganda. NV-387 is designed to mimic sulfated proteoglycans used by filoviruses for cell attachment.
The drug is room‑temperature stable, formulated as oral gummies, and is being advanced toward Phase II clinical trials for respiratory and poxvirus infections. NanoViricides holds broad exclusive licenses for antiviral nanomedicine technology from TheraCour and is developing candidates against multiple serious viral diseases.